Is dapagliflozin appropriate for a patient with chronic kidney disease (CKD) stage 1, and what dosing and monitoring are recommended?

Dapagliflozin in CKD Stage 1: Appropriate Use and Clinical Guidance

Dapagliflozin is appropriate for patients with CKD stage 1 (eGFR ≥90 mL/min/1.73 m²) when specific cardiovascular or renal risk factors are present, but it should not be initiated solely for glycemic control in the absence of these indications. 1

Indication-Based Prescribing in CKD Stage 1

For Chronic Kidney Disease at Risk of Progression

• Dapagliflozin 10 mg once daily is FDA-approved to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and heart failure hospitalization in adults with CKD at risk of progression. 1
• The drug is most appropriate when albuminuria is present (UACR ≥200 mg/g), as this defines "CKD at risk of progression" in the pivotal DAPA-CKD trial. 2
• KDIGO 2022 gives a strong (1A) recommendation for SGLT2 inhibitor use when eGFR ≥20 mL/min/1.73 m² and UACR ≥200 mg/g, regardless of diabetes status. 3
• For patients with UACR <200 mg/g, KDIGO provides a weaker (2B) recommendation, though real-world data suggest benefit even at lower albuminuria levels. 4, 5

For Type 2 Diabetes with Cardiovascular Risk

• In patients with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, dapagliflozin 10 mg daily reduces heart failure hospitalization risk, independent of baseline eGFR. 1, 6
• The 2025 ADA Standards recommend SGLT2 inhibitors for patients with type 2 diabetes and cardiovascular disease or high cardiovascular risk, regardless of A1C or baseline glucose-lowering therapy. 6

For Glycemic Control Alone

• When the sole indication is glycemic control in type 2 diabetes without cardiovascular disease or albuminuria, start with 5 mg once daily and may increase to 10 mg for additional glucose-lowering effect. 1
• At eGFR ≥90 mL/min/1.73 m² (stage 1 CKD), dapagliflozin retains full glucose-lowering efficacy, unlike in advanced CKD where this effect is lost below eGFR 45 mL/min/1.73 m². 1

Dosing Recommendations by Indication

Cardiovascular or Renal Protection

• Prescribe dapagliflozin 10 mg once daily when the indication is CKD progression risk, heart failure, or cardiovascular risk reduction—do not use the 5 mg dose for these indications. 1, 7

Glycemic Control

• Start with 5 mg once daily; titrate to 10 mg if additional glucose lowering is needed and the patient tolerates the lower dose. 1

Pre-Initiation Assessment

Volume Status and Diuretic Management

• Assess volume status before starting dapagliflozin; correct any volume depletion to avoid hypotension or acute kidney injury. 1, 3
• In patients receiving loop or thiazide diuretics who appear volume-depleted or have low blood pressure, reduce the diuretic dose by 30–50% before initiating dapagliflozin. 7, 4

Glycemic Therapy Adjustment

• If the patient with diabetes is already meeting glycemic targets, lower insulin dose by approximately 20% or decrease sulfonylurea dose when starting dapagliflozin to prevent hypoglycemia. 7, 4

Baseline Laboratory Assessment

• Measure eGFR and UACR at baseline to confirm the indication and establish a reference for monitoring. 1
• Check serum potassium to ensure it is within normal range, as dapagliflozin reduces hyperkalemia risk but should not be started in the setting of severe hyperkalemia. 3, 4

Expected Renal Effects and Monitoring

Early eGFR Dip

• An initial decline in eGFR of 2–5 mL/min/1.73 m² within the first 2–4 weeks is typical and reflects reversible hemodynamic changes (reduced intraglomerular pressure), not kidney injury. 3, 7
• Do not discontinue dapagliflozin solely because of this early dip; it is an expected pharmacodynamic effect that does not predict long-term harm. 3, 4

Long-Term Renal Trajectory

• After the initial dip, eGFR typically stabilizes and the long-term decline slope is attenuated compared to placebo, as demonstrated in DAPA-CKD. 2, 8
• Re-measure eGFR at 2–4 weeks after initiation, then periodically (e.g., every 3–6 months) based on CKD stage and clinical stability. 3

Albuminuria Reduction

• Dapagliflozin reduces albuminuria by approximately 25% within 4 months in real-world cohorts, with nearly half of patients achieving ≥30% reduction. 9

Safety Considerations and Patient Education

Genital Mycotic Infections

• Genital mycotic infections occur in approximately 6–10% of users, more commonly in women and uncircumcised men. 4, 10
• Provide hygiene counseling at initiation; most infections can be managed with topical antifungals without discontinuing dapagliflozin. 4

Euglycemic Diabetic Ketoacidosis

• Educate patients on "sick-day rules": hold dapagliflozin during acute illness with nausea, vomiting, diarrhea, prolonged fasting, or before major surgery (withhold at least 3 days prior). 1, 3
• This rare but serious adverse event is more likely during metabolic stress, even when blood glucose is not markedly elevated. 3

Hypotension and Volume Depletion

• Monitor blood pressure and volume status at follow-up visits, especially in older adults (≥65 years) who have higher hypotension risk. 1, 4
• Advise patients to recognize symptoms of volume depletion (dizziness, lightheadedness) and to maintain adequate hydration. 3

Hyperkalemia Mitigation

• Dapagliflozin reduces hyperkalemia risk without causing hypokalemia, facilitating safe concurrent use of ACE inhibitors, ARBs, or mineralocorticoid receptor antagonists. 4, 3

Common Pitfalls to Avoid

Do Not Withhold Based on eGFR Alone

• At eGFR ≥90 mL/min/1.73 m² (stage 1 CKD), there is no eGFR-based contraindication to dapagliflozin initiation for any approved indication. 1
• The eGFR threshold of 25 mL/min/1.73 m² applies only to initiation for non-glycemic indications; stage 1 CKD is well above this cutoff. 1

Do Not Stop for the Early eGFR Dip

• The initial 2–5 mL/min/1.73 m² decline is hemodynamic and reversible; stopping therapy prematurely deprives the patient of long-term cardiovascular and renal protection. 3, 7

Do Not Use 5 mg for Cardiovascular or Renal Protection

• The 5 mg dose is approved only for glycemic control; all cardiovascular and renal outcome trials used 10 mg daily. 1, 2

Do Not Combine with Other SGLT2 Inhibitors

• No additive benefit has been demonstrated; use only one SGLT2 inhibitor at a time. 7

Synergy with Renin-Angiotensin System Inhibition

Complementary Mechanisms

• Dapagliflozin and ACE inhibitors or ARBs act through distinct pathways to lower intraglomerular pressure, providing additive kidney protection without increasing adverse events. 7
• Do not withhold dapagliflozin solely because the patient is already on an ACE inhibitor or ARB; the combination is safe and recommended. 7, 3

Monitoring the Combination

• Reassess blood pressure and volume status at follow-up, as the combination can produce additive diuretic effects. 7
• Monitor serum potassium periodically, though dapagliflozin actually reduces hyperkalemia risk when combined with RAS inhibitors. 4

Quality of Life and Patient-Centered Outcomes

• In DAPA-CKD, dapagliflozin slowed the decline in physical health scores, reduced worsening of kidney disease symptoms, and lessened the burden of kidney disease on daily life. 11
• Patients randomized to dapagliflozin were 16% less likely to experience a clinically meaningful (≥10-unit) decline in physical health composite scores. 11